拓扑替康联合顺铂治疗晚期肺鳞癌的初步临床研究  

A clinical study on the combination of topotecan and cisplatin in treatment of advanced non-small cell lung cancer

作　　者：刘刚[1] 杨和平[1] 胡建林[1] 王政惠[1] 

机构地区：[1]第三军医大学西南医院呼吸科,重庆400038

出　　处：《重庆医学》2002年第9期786-788,共3页Chongqing medicine

摘　　要：目的　观察拓扑替康联合顺铂治疗晚期肺鳞癌的疗效和毒副反应。方法　经病理组织学或细胞学证实的 4 6例肺鳞癌患者给予拓扑替康 1.0～ 1.2mg/m2 静滴 ,第 1～ 5天 ,顺铂 6 0～ 80mg/m2 静滴 ,第六天 ,2 1d为一周期。结果　全组无CR ,PR2 3例 ,SD 15例 ,PD 8例 ,31例初治者和 15例复治者近期有效率分别为 5 4 .8%、4 0 .0 % ,总有效率 5 0 .0 %。中位生存期 10个月(4～ 15个月 ) ,1年生存率为 32 .6 %。毒副反应主要有骨髓抑制、胃肠道反应及轻度脱发。结论　拓扑替康联合顺铂治疗肺鳞癌具有较好的疗效 。Objective To evaluvate the efficacy and toxicity of the combination of topotecan and cisplatin in treatment of patients with advanced non small cell lung cancer(NSCLC).Methods Forty six patients with locally advanced (stage III) or metastatic (stage IV) NSCLC were enrolled into the study. The patients received topotecan 1.0～1.2 mg/m2 on day 1 5, and cisplatin 60～80mg/m2 on day 6 of the 21 day cycle. Results An objective response was obtained in 50.0% of patients (23 partial responses), whereas 15 patients had stable disease and 8 patients were progressive. The response rate was 54.8% in patients with no prior chemotherapy, and the response rate of 40.0% was achieved in patients who had given prior treatment. No significant difference existed between the two groups ( P >0.05). The median duration of survival was 10 months, and 1 year survival rate was 32.6%. Toxicity was chiefly hematologic in the form of neutropenia. The major nonhematologic toxicity was nausea or vomiting and alopecia. Conclusion The combination of topotecan and cisplatin is a feasible ,well tolerated, and active scheme in treatment of advanced NSCLC.

关 键 词：拓扑替康 顺铂 晚期肺鳞癌 临床研究 药物疗法 联合治疗 

分 类 号：R734.2[医药卫生—肿瘤] R979.1[医药卫生—临床医学]